Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2012. The report details a specific share repurchase transaction executed on October 8, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 375,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,456.5 pence per share; lowest price paid was 1,443.5 pence per share.
- Treasury Holdings (Settled): 503,965,427 shares (9.26% of total issued share capital).
- Treasury Holdings (Including Unsettled): 504,840,427 shares (10.22% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,941,015,528 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 375,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 10.22% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (503,965,427 settled) against the company's latest 20-F annual report.
- Confirm the total issued share capital to validate the 9.26% Treasury ownership calculation.
- Check the status of the 875,000 shares (difference between settled and total Treasury holdings) to confirm settlement dates.
- Review the Financial Services Authority's Disclosure and Transparency Rules to understand notification thresholds based on the 4,941,015,528 shares in issue.